Nurix Therapeutics reported Q3 FY25 results with lower revenue and a larger net loss compared to the prior year, as the company increased spending to support the clinical advancement of its pipeline, including bexobrutideg.
Revenue fell to $7.9M from $12.6M YoY due to lower Sanofi collaboration revenue
Net loss widened to $86.4M from $49.0M YoY
R&D expenses increased significantly to support trial readiness for bexobrutideg
Strong liquidity position with $428.8M in cash and marketable securities
Nurix plans to initiate pivotal trials for bexobrutideg in Q4 2025, expand into autoimmune indications, and continue advancing its partnered programs.
Analyze how earnings announcements historically affect stock price performance